受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C21H24F3N5O5S |
|||
分子量 | 515.51 | CAS No. | 1448671-31-5 | |
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (193.98 mM) | |
Ethanol | 100 mg/mL (193.98 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | AZD3965 is a potent, selective and orally available monocarboxylate transporter 1 (MCT1) inhibitor with a binding affinity of 1.6 nM, 6-fold selective over MCT2. Phase 1. |
---|---|
in vitro | In lymphoma cell lines that preferentially express MCT1, AZD3965 potently inhibits lactate transport and cell growth. [1] AZD3965 inhibits MCT1 activity in cells, and shows higher sensitivity in hypoxia. [2] In H526, HGC27 cells and DMS114 cells, AZD3965 increases intracellular lactate and significantly reduces lactate uptake. [3] |
in vivo | In nonobese diabetic scid-γ mice bearing COR-L103 xenografts, AZD3965 (100 mg/kg, p.o.) reduces tumor growth and increased intratumor lactate. [2] In mice bearing H526 tumors, AZD3965 (100 mg/kg, p.o.) causes increased lactate concentration, a reduction in growth and increased radiation sensitivity. [3] |
細胞アッセイ | 細胞株 | DMS114, H526 and HGC27 cells |
---|---|---|
濃度 | 1.6 nM | |
反応時間 | 24 h | |
実験の流れ | Cells were incubated in either normoxia, 1% oxygen (hypoxia) or anoxia in complete media supplemented with AZD3965 or DMSO vehicle for 24 hours. |
|
動物実験 | 動物モデル | Nonobese diabetic scid-γ mice bearing COR-L103 xenografts |
投薬量 | 100 mg/kg | |
投与方法 | p.o. |
|
Data from [Data independently produced by , , Cancer Res, 2017, 77(20):5591-5601]
Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression [ Biomark Res, 2024, 12(1):48] | PubMed: 38730450 |
H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response [ Cell Rep, 2024, 43(9):114686] | PubMed: 39216002 |
Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression [ J Cachexia Sarcopenia Muscle, 2023, 10.1002/jcsm.13363] | PubMed: 37919243 |
A critical role for heme synthesis and succinate in the regulation of pluripotent states transitions [ Elife, 2023, 12e78546] | PubMed: 37428012 |
A critical role for heme synthesis and succinate in the regulation of pluripotent states transitions [ Elife, 2023, 12e78546] | PubMed: 37428012 |
A critical role for heme synthesis and succinate in the regulation of pluripotent states transitions [ Elife, 2023, 12e78546] | PubMed: 37428012 |
Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis [ J Orthop Surg Res, 2023, 18(1):131] | PubMed: 36814318 |
The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62 [ Cell Rep, 2022, 39(6):110792] | PubMed: 35545049 |
Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation [ Cell Rep, 2022, 40(7):111193] | PubMed: 35977513 |
A Heme-Binding Transcription Factor BACH1 Regulates Lactate Catabolism Suggesting a Combined Therapy for Triple-Negative Breast Cancer [ Cells, 2022, 11(7)1177] | PubMed: 35406740 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。